I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

*I*ncreased circulating insulin levels contribute to hyperandrogenism in women with polycystic ovarian syndrome (PCOS). Hyperandrogenism causes a derangement in folliculogenesis, thus contributing to the polycystic morphogenesis of the ovaries and a higher than normal anti-Mullerian hormone (AMH). A high AMH is said to be an indicator of either stubborn anovulation or a predictor of ovarian hyperstimulation syndrome. Hence, it is postulated that the use of insulin sensitizers would reduce the insulin resistance, hyperandrogenemia, and subsequently serum AMH levels and would convert anovulatory cycles to ovulatory. The hormonal and metabolic milieu thus corrected would improve response to stimulation in the subsequent *in vitro* fertilization (IVF) cycles.

Study design {#sec2-1}
------------

A prospective interventional randomized single-center study conducted from August 2015 to April 2016. The study protocol was approved by the local ethics committee and written informed consent was obtained from all participants.

Inclusion criteria {#sec2-2}
------------------

Infertile patients with PCOS as defined by the Rotterdam criteria, namely at least two out of the following three:

Menstrual disorders defined as oligomenorrhea (cycle length \>35 days) or amenorrhea (cycle length \>12 weeks)Clinical hyperandrogenism (modified Ferriman--Gallwey score \[mFGS\] of ≥6, presence of acne, or seborrhea) and/or biochemical evidence of hyperandrogenemiaPatients with Polycystic ovaries on ultrasound (12 or more measuring 2--9 mm in diameter (mean of both ovaries) and day 2 (D2)/D3 serum AMH levels \>5 ng/ml, irrespective of the body mass index (BMI), were included.

Exclusion criteria {#sec2-3}
------------------

Women with other causes of PCOs on ultrasound due to anovulation such as hyperprolactinemia, thyroid disorders, late-onset congenital adrenal hyperplasia, and Cushing\'s syndrome by the use of appropriate testsPCOS patients with AMH \<5 ng/mlPatients with contraindications to use of insulin sensitizers such as metformin due to prior adverse effectsUsage of oral contraceptive and/or any other insulin sensitizer in the previous 3 months.

M[ETHODOLOGY]{.smallcaps} {#sec1-2}
=========================

Infertile PCOS patients visiting the outpatient department were evaluated in the early follicular phase following spontaneous or progesterone-induced menstruation (cycle day 2--3). Their age, type of infertility (primary or secondary), cycle regularity, height, weight, BMI, clinical evidence of hyperandrogenism (based on mFGS), presence and grade of acne (based on the score by the Indian Acne Society), and prior response to ovarian stimulation (if any) were noted. Peripheral venipuncture to assess serum hormonal concentrations of AMH was done. Transvaginal scan was done to assess the base line antral follicle count (AFC). The sample size was 105 patients. Once the patients met the inclusion criteria and did not fall into any exclusion criteria, as described above, drug randomization was done using the computer-generated tables. They received any one of the following insulin sensitizers:

Group A: Tablet metformin 850 mg twice a day alone (*n* = 35)Group B: Tablet metformin 850 mg twice a day plus tablet myoinositol 2 g twice a day (*n* = 35)Group C: Tablet myoinositol 2 g twice a day alone (*n* = 35).

The therapy was continued for 3 months.

The test subjects were their own controls.

At the end of this period, the following parameters were rechecked.

Cycle regularityBMIClinical evidence of hyperandrogenism (based on mFGS)Presence and grade of acne (based on the score by the Indian Acne Society)Serum AMHAFC.

The primary outcome was:

Change in serum AMH levels.

The secondary outcomes were:

Cycle regularityChange in AFCChange in mFGSChange in acne score.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

There were 10 dropouts of the study with 95 subjects remaining. Statistical analysis was done using univariate analysis and Chi-square tests in SPSS Version 20 (IBM, Armonk, NY, USA).

[Table 1](#T1){ref-type="table"} summarizes the baseline parameters at the start of the study. As can be seen, the age is comparable in all the three groups with no statistically significant difference. Serum AMH levels were comparable in all the three groups with no statistically significant difference. The number of patients in the primary and secondary infertility group was also comparable in all the three groups. The AFC, however, had a statistically significant difference in all the three groups at the start with the highest AFC in myoinositol only group.

###### 

Baseline characteristics of the study groups
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[Table 2](#T2){ref-type="table"} shows the results at the end of 3 months of treatment. There was a significant fall in serum AMH levels in all the three groups. The maximum fall was in the group that received only metformin.

###### 

Comparison of anti-Mullerian hormone levels and antral follicle count before and after treatment with insulin sensitizers
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[Table 3](#T3){ref-type="table"} compares the cycle regularity before and after treatment with insulin sensitizers. Cycles became regular in all the three groups with the maximum numbers seen in the group which received both the insulin sensitizers.

###### 

Comparison of cycle regularity before and after treatment with insulin sensitizers
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[Table 4](#T4){ref-type="table"} shows the change in the grade of hirsutism as shown by the mFGS. There was a significant reduction in the hirsutism score in all the groups. In Group A, the percentage of patients with grade 2 hirsutism reduced and the percentage in grade 1 increased as compared to before treatment. Similarly, in Group B, the percentage of patients with grade 2 hirsutism reduced and the percentage in grade 1 increased. In Group C, the percentage of patients with grade 1 hirsutism reduced and the percentage of grade 0 increased. Overall, there was reduction in hirsutism with the use of insulin sensitizers.

###### 

Comparison of modified Ferriman-Gallwey score before and after treatment with insulin sensitizers
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[Table 5](#T5){ref-type="table"} shows the change in the grade of acne as shown by the acne score. There was a significant reduction in the acne score in all the groups. In Group A, the percentage of patients with grade 2 acne reduced and the percentage in grade 1 increased as compared to before treatment. Similarly, in Group B, the percentage of patients with grade 2 acne reduced and the percentage in grade 1 increased. In Group C, the percentage of patients with grade 2 acne reduced and the percentage of grade 1 increased. Overall, there was reduction in acne score with the use of insulin sensitizers.

###### 

Comparison of grade of acne before and after treatment with insulin sensitizers
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D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Insulin resistance is a common feature in obese and to a lesser extent in lean PCOS. Insulin sensitivity is decreased up to 35%--40% in women with PCOS in comparison to normal women.\[[@ref1]\] Increased circulating insulin levels cause hyperandrogenism in these women by stimulating increased ovarian androgen production and by inhibiting hepatic sex hormone-binding globulin production.\[[@ref1]\] Insulin and luteinizing hormone (LH) act synergistically to cause hyperandrogenism.\[[@ref1]\]

High local androgen concentrations contribute to the polycystic morphogenesis of the ovaries. They do so by conversion to more potent 5a-reduced androgens. These cannot be aromatized to estrogen. They also inhibit aromatase activity and follicle-stimulating hormone (FSH) induction of LH receptors on Granulosa cells. This impedes progressive follicular development. Thus, new follicular growth does occur but arrests before full maturation. This leads to multiple small cysts measuring 2--10 mm in diameter surrounded by hyperplastic theca cells. These atretic follicles contribute to an expanding ovarian stroma that increases in volume over time and starts a self-propagating cycle of hyperandrogenism and chronic anovulation.\[[@ref1]\]

AMH, also known as Mullerian-inhibiting substance, belongs to the transforming growth factor-beta superfamily of proteins that includes activins, inhibins, bone morphogenetic proteins, and growth determining factors. The gene for AMH is found on chromosome 19. Initially, it was known to have a role in the sexual differentiation in male fetus *in utero* but has recently been found to have a role in female reproductive physiology. Produced in the highest concentration by the preantral and small antral follicles from 36 weeks of intrauterine life till menopause, the role of AMH has been extensively studied. AMH is a known test of the ovarian reserve and reflects the leftover follicular pool. It serves as a predictor of the IVF success by indirectly correlating with the oocyte yield and quantity. AMH prevents the recruitment of primordial follicles. Low AMH levels thus allow more primordial follicular recruitment and faster exhaustion of the ovarian reserve. AMH prevents the FSH-mediated estrogen production from the preantral and small antral follicles by inhibiting the aromatase enzyme and reducing the levels of LH receptors, thereby preventing the follicular growth. Levels start reducing once the follicle reaches 10 mm size and further reduces as it attains dominance. High AMH prevents dominance.

AMH levels in women with PCOS are 2--3 times higher than normal women. AMH production is 75 times higher from granulosa cells from anovulatory PCOS than normal granulosa cells. The levels in anovulatory PCOS are 5 times higher than ovulatory PCOS. The reason for the increased AMH in PCOS could either be due to the increase in the number of the preantral and small antral follicles in women with PCOS as compared to non-PCOS or due to the associated hyperandrogenism and insulin resistance as explained above. It has been demonstrated that granulosa cells of women with PCOS intrinsically produce more AMH than non PCOS women.

PCOS women can be ovulatory or anovulatory. The levels of AMH in ovulatory PCO are higher than normal but lower than anovulatory PCOS in whom it is 18 times higher. The reason could be higher androgens in the anovulatory subgroup than the ovulatory ones.

Thus, it was postulated that the use of insulin sensitizer drugs such as metformin and myoinositol would reduce the insulin resistance and consequently hyperandrogenism, serum AMH levels, and D2--AFC and would convert anovulatory PCO patients to ovulatory. The hormonal and metabolic milieu thus corrected was postulated to improve response to stimulation in the subsequent IVF cycles.

On reviewing the literature, we found no study comparing all the three groups. Hence, each of the insulin sensitizers were considered individually and studies comparing the parameters under study were searched.

When the literature was reviewed for metformin alone, four studies similar to our study were studied. The serum AMH levels fell in the study by Saleh *et al*.,\[[@ref2]\] Neagu and Cristescu,\[[@ref3]\] and Tomova *et al*.\[[@ref4]\] similar to what we had observed in our study. However, in the study by Nascimento *et al*.,\[[@ref5]\] there was no significant change in the serum AMH levels.

When the AFC was compared between the studies, Saleh *et al*.\[[@ref2]\] and Neagu and Cristescu\[[@ref3]\] saw a drop in the same. This parameter was not studied by Tomova *et al*.\[[@ref4]\] and Nascimento *et al*.\[[@ref5]\] We saw a fall in the AFC, but whether it was statistically significant in one group as compared to the other cannot be commented upon as there was a significant intergroup variation at the start.

In all the studies discussed above, cycle regularity was attained after treatment. This is indirect evidence to the conversion of anovulatory to ovulatory status.

There was an improvement in hirsutism in the study by Saleh *et al*.\[[@ref2]\] and Nascimento *et al*.\[[@ref5]\] as was witnessed by us. The other two study groups referred to earlier did not study the parameter.

When a search was made in PubMed, no study was found that showed any effect of insulin sensitizer inositol on serum AMH levels. As for the other parameters such as cycle regularity, improvement in hirsutism, and acne score, the studies by Genazzani *et al*.,\[[@ref6]\] Costantino *et al*.,\[[@ref7]\] and Angik *et al*.\[[@ref8]\] showed results similar to ours.

AFC was studied by Angik *et al*.\[[@ref8]\] and was found reduced after treatment similar to our study result.

In the literature searched, only one study by Ali *et al*.\[[@ref9]\] compared the effect of both metformin and myoinositol combined on the parameters studied. The AMH levels reduced, cycles became regular with an improvement in the clinical hyperandrogenism and acne score. This group however did not study the effect of the drugs on the AFC.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

The following conclusions can be drawn from the study conducted regarding therapy with insulin sensitizers in PCOS:

Reduces serum AMH levelsConverts irregular cycles to regularReduces clinical hyperandrogenismMinimum duration of therapy-3 months.

Merits {#sec2-4}
------

First of its kindProspective randomizedSingle-centerSingle observerAdequate sample size.

Demerits {#sec2-5}
--------

Effect of longer duration of the treatment needs to be seen in patients who did not respondEffect of the treated patients in stimulation cycles needs to be seenThe correlation of BMI with insulin resistance could not be seen.
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